Literature DB >> 19591064

Inquiries about and initiation of buprenorphine treatment in an inner-city clinic.

Chinazo O Cunningham1, Angela Giovanniello, Galit Sacajiu, Xuan Li, Mia Brisbane, Nancy L Sohler.   

Abstract

Despite increases in opioid dependence, availability of buprenorphine treatment remains limited. Reasons may include health center concerns about becoming overwhelmed or attracting patients who differ from the local community. This study documents inquiries about and initiation of buprenorphine treatment in an inner-city health center. From 2006-2008, we collected demographic information and subsequent treatment data for everyone who inquired about treatment. Of the 324 people who inquired, 55.6% initiated treatment. The number of inquiries increased gradually over time, and most came from local community residents (80.4%). These results may allay health center concerns, and can help planning for buprenorphine treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19591064      PMCID: PMC2746741          DOI: 10.1080/08897070903041301

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  3 in total

1.  Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.

Authors:  Barbara J Turner; Christine Laine; Yi-Ting Lin; Kevin Lynch
Journal:  Arch Intern Med       Date:  2005 Aug 8-22

2.  The first three years of buprenorphine in the United States: experience to date and future directions.

Authors:  David A Fiellin
Journal:  J Addict Med       Date:  2007-06       Impact factor: 3.702

3.  Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians.

Authors:  Chinazo O Cunningham; Hillary V Kunins; Robert J Roose; Rashiah T Elam; Nancy L Sohler
Journal:  J Gen Intern Med       Date:  2007-07-10       Impact factor: 5.128

  3 in total
  2 in total

1.  Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.

Authors:  Andrea Jakubowski; Tiffany Lu; Frank DiRenno; Benjamin Jadow; Angela Giovanniello; Shadi Nahvi; Chinazo Cunningham; Aaron Fox
Journal:  J Subst Abuse Treat       Date:  2020-09-22

Review 2.  Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Authors:  E Jennifer Edelman; David A Fiellin
Journal:  Am J Prev Med       Date:  2013-01       Impact factor: 5.043

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.